Temozolomide in children with progressive low-grade glioma

We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma. Thirty eligible patients were enrolled on this study. Median age at enrollment was 10 years (range, 4–18 years). Eligible patients received TMZ (200 mg/m(2) per day) by mout...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Gururangan, Sridharan, Fisher, Michael J., Allen, Jeffrey C., Herndon, James E., Quinn, Jennifer A., Reardon, David A., Vredenburgh, James J., Desjardins, Annick, Phillips, Peter C., Watral, Melody A., Krauser, Jeanne M., Friedman, Allan H., Friedman, Henry S.
Формат: Artigo
Язык:Inglês
Опубликовано: Duke University Press 2007
Предметы:
Special Focus: Pediatric Neuro-Oncology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC1871667/
https://ncbi.nlm.nih.gov/pubmed/17347491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2006-030
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы